{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT02088060","title":"A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients","sponsor":"Central Institute of Mental Health, Mannheim","phases":["PHASE2"],"status":"TERMINATED","indication":null,"disease":"schizophrenia"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"no","detail":"None of CNR1, HTR2A, HTR2C, DRD2 has somatic-mutation evidence in schizophrenia","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: CNR1 in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000118432/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"},"context":[]},{"id":"human_genetic","label":"Human genetic evidence","value":"yes","detail":"DRD2: germline","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: DRD2 in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000149295/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"},"context":[{"figure":"2.6× relative probability of success, phase 1 to launch, with human genetic support","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"All therapy areas, mostly germline evidence; not a probability for this program."}]},{"id":"pediatric_target","label":"Pediatric target","value":"no","detail":"Not on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"no","detail":"Solid tumour","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"CNR1 (via Cannabidiol)","text":"Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: CNR1 in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000118432/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"}},{"label":"HTR2A (via Olanzapine)","text":"Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: HTR2A in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000102468/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"}},{"label":"HTR2C (via Olanzapine)","text":"Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: HTR2C in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000147246/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"}},{"label":"DRD2 (via Olanzapine)","text":"Evidence types in schizophrenia: literature, animal_model, genetic_association, clinical; literature and animal_model listed separately from human genetics. Datasources: clinical_precedence, gwas_credible_sets, europepmc, impc, eva.","source":{"label":"Open Targets: DRD2 in schizophrenia","url":"https://platform.opentargets.org/evidence/ENSG00000149295/MONDO_0005090","date":"2026-11-12T00:25:32.505Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"yes","detail":"Randomised allocation","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"150 planned; each patient moves a rate by 100 ÷ 150 = 0.7 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Change in the Positive and Negative Syndrome Scale (PANSS) total score","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"yes","detail":"Primary completion 2024-09-16, 25 months ago; no results posted","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},"context":[{"figure":"40.9% of applicable trials report results within a year","dataset":"Results-reporting studies summarised in spec §11","years":"all therapy areas","caveat":"All areas, not oncology only."}]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"118 terminated, withdrawn or suspended trials of drugs against CNR1; 4 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"CNR1: what already stopped","url":"/target/ENSG00000118432#stopped","date":"2026-11-12T00:25:32.510Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"no","detail":"6 sites in 2 countries; 0 in the United States (0%)","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060?tab=locations","date":"2026-11-12T00:25:32.505Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMEA-001964-PIP02-19 (cannabidiol, Treatment of Rett syndrome): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 18 Mar 2020; EMEA-001964-PIP03-21 (cannabidiol, Epilepsy with myoclonic atonic seizures): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 8 Jul 2022; EMA/PE/0000224912 (cannabidiol, Treatment of seizures associated with Dravet Syndrome (DS);Treatment of seizures associated with Lennox-Gastaut Syndrome (LGS);Treatment of seizures associated with Tuberous Sclerosis Complex (TSC)): PM: decision on the application for modification of an agreed PIP, 3 Jan 2025; EMEA-003176-PIP02-22 (cannabidiol, Treatment of fragile-X syndrome): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 15 Mar 2024; +2 more","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/23/2800 positive 25 Jul 2023: Treatment of Leigh syndrome; EU/3/22/2600 positive 13 Apr 2022: Treatment of epilepsy with myoclonic-atonic seizures; EU/3/17/1959 positive 17 Jan 2018: Treatment of tuberous sclerosis; EU/3/17/1920 positive 16 Oct 2017: Treatment of West syndrome; +10 more","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Epidyolex: authorised since 19 Sept 2019, orphan medicine; Olazax: authorised since 11 Dec 2009; Zypadhera: authorised since 19 Nov 2008; Olazax Disperzi: authorised since 10 Dec 2009; +10 more","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"no","detail":"FDA's table lists no pediatric approval of Cannabidiol, Olanzapine","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-12T00:25:32.521Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"159 interventional studies of Cannabidiol, Olanzapine include patients under 18; 28 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Cannabidiol%22+OR+%22Olanzapine%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-12T00:25:32.525Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"Central Institute of Mental Health, Mannheim (academic or other)","source":{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"}},{"label":"principal investigator","text":"F. Markus Leweke, MD, Central Institute of Mental Health","source":{"label":"Person page","url":"/person/F.%20Markus%20Leweke%2C%20MD","date":"2026-11-12T00:25:32.505Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT02088060","url":"https://clinicaltrials.gov/study/NCT02088060","date":"2026-11-12T00:25:32.505Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-12T00:25:32.505Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-12T00:25:32.504Z"}